A detailed history of Orbimed Advisors LLC transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Orbimed Advisors LLC holds 4,533,801 shares of ADCT stock, worth $8.98 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
4,533,801
Previous 4,316,824 5.03%
Holding current value
$8.98 Million
Previous $13.6 Million 4.69%
% of portfolio
0.34%
Previous 0.33%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.59 - $4.01 $561,970 - $870,077
216,977 Added 5.03%
4,533,801 $14.3 Million
Q2 2024

Aug 14, 2024

BUY
$2.55 - $5.09 $11 Million - $22 Million
4,316,824 New
4,316,824 $13.6 Million

Others Institutions Holding ADCT

About ADC Therapeutics SA


  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $154M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.